Gerald McMahon

16.2k total citations · 4 hit papers
77 papers, 11.8k citations indexed

About

Gerald McMahon is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Gerald McMahon has authored 77 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 25 papers in Cancer Research and 16 papers in Oncology. Recurrent topics in Gerald McMahon's work include Angiogenesis and VEGF in Cancer (25 papers), Cancer, Hypoxia, and Metabolism (16 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Gerald McMahon is often cited by papers focused on Angiogenesis and VEGF in Cancer (25 papers), Cancer, Hypoxia, and Metabolism (16 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Gerald McMahon collaborates with scholars based in United States, Japan and Germany. Gerald McMahon's co-authors include Cho Tang, Li Sun, Gabriele Bergers, Douglas Hanahan, Zena Werb, Takeshi Itoh, Thiennu H. Vu, Kazuhiko Tamaki, Philip E. Thorpe and Shigeyoshi Itohara and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Gerald McMahon

77 papers receiving 11.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

2000 2.2k citations Gabriele Bergers, Rolf A. Brekken et al. Nature Cell Biology profile →
Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

1997 960 citations Gerald McMahon, Cho Tang et al. profile →
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

1999 885 citations Cho Tang, Gerald McMahon et al. PubMed profile →
Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids

1995 598 citations Ker Yu, William Bayona et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald McMahon United States	45	7.0k	3.1k	2.9k	1.4k	1.2k	77	11.8k
Evelyn Flynn United States	36	6.8k 1.0×	2.5k 0.8×	3.1k 1.1×	1.1k 0.8×	864 0.7×	66	11.4k
Gary E. Gallick United States	67	7.7k 1.1×	6.0k 2.0×	2.9k 1.0×	2.0k 1.4×	1.0k 0.8×	202	13.7k
Motowo Nakajima Japan	54	5.9k 0.8×	2.7k 0.9×	2.2k 0.8×	1.1k 0.8×	793 0.6×	225	10.3k
Helen Turley United Kingdom	65	10.0k 1.4×	3.9k 1.3×	7.4k 2.6×	2.0k 1.4×	1.5k 1.2×	149	15.9k
Surender Kharbanda United States	70	12.1k 1.7×	4.0k 1.3×	2.1k 0.7×	545 0.4×	2.2k 1.8×	191	15.5k
Alfonso Bellacosa United States	52	10.8k 1.5×	4.0k 1.3×	2.3k 0.8×	877 0.6×	1.3k 1.1×	118	14.4k
Robert B. Dickson United States	73	8.9k 1.3×	5.9k 1.9×	3.6k 1.3×	871 0.6×	1.2k 0.9×	221	16.1k
Dieter Marmé Germany	58	8.1k 1.2×	2.1k 0.7×	2.1k 0.7×	814 0.6×	934 0.8×	140	11.4k
Atanasio Pandiella Spain	57	6.6k 0.9×	4.9k 1.6×	1.5k 0.5×	1.2k 0.8×	1.3k 1.0×	284	11.6k
David Stokoe United States	53	11.5k 1.7×	3.5k 1.1×	2.5k 0.9×	1.2k 0.8×	2.1k 1.7×	96	15.7k

Countries citing papers authored by Gerald McMahon

Since Specialization

Citations

This map shows the geographic impact of Gerald McMahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald McMahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald McMahon more than expected).

Fields of papers citing papers by Gerald McMahon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald McMahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald McMahon. The network helps show where Gerald McMahon may publish in the future.

Co-authorship network of co-authors of Gerald McMahon

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald McMahon. A scholar is included among the top collaborators of Gerald McMahon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald McMahon. Gerald McMahon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

London, Cheryl A., Heather L. Gardner, Gerald Post, et al.. (2016). KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research. 23(10). 2565–2574. 29 indexed citations

Yang, Yan, Sreekala Mandiyan, Brett S. Robinson, & Gerald McMahon. (2016). Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors. Cancer Research. 76(19). 5788–5797. 3 indexed citations

LaVallee, Theresa, Diego Alvarado, Andrew J. Garton, et al.. (2015). Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders. Critical Reviews™ in Oncogenesis. 20(5-6). 485–508. 4 indexed citations

Tang, Chi‐Hui, et al.. (2010). Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemotherapy and Pharmacology. 67(6). 1389–1400. 44 indexed citations

Abdollahi, Amir, Minglun Li, Ping Gong, et al.. (2005). Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. The Journal of Experimental Medicine. 201(6). 925–935. 311 indexed citations

Bova, Michael P., et al.. (2004). Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicology Letters. 155(1). 41–50. 68 indexed citations

Bova, Michael P., Stefan Vasile, Danny Tam, et al.. (2004). The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase α is mediated by hydrogen peroxide. Archives of Biochemistry and Biophysics. 429(1). 30–41. 48 indexed citations

London, Cheryl A., Alison L. Hannah, May Chien, et al.. (2003). Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.. PubMed. 9(7). 2755–68. 220 indexed citations

Tille, Jean‐Christophe, Xueyan Wang, Kenneth E. Lipson, et al.. (2003). Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CΔNΔC- and VEGF-A-induced angiogenesis in vitro. Experimental Cell Research. 285(2). 286–298. 33 indexed citations

10.

Lund, Eva Løbner, et al.. (2003). Improved Effect of an Antiangiogenic Tyrosine Kinase Inhibitor (SU5416) by Combinations with Fractionated Radiotherapy or Low Molecular Weight Heparin. Neoplasia. 5(2). 155–160. 19 indexed citations

11.

Huang, Ping, John Ramphal, James Cheng‐Chung Wei, et al.. (2003). Structure-Based design and discovery of novel inhibitors of protein tyrosine phosphatases. Bioorganic & Medicinal Chemistry. 11(8). 1835–1849. 51 indexed citations

12.

Kish, Phillip E., Mila Blaivas, Myla Strawderman, et al.. (2001). Magnetic Resonance Imaging of Ethyl-nitrosourea-induced Rat Gliomas: A Model for Experimental Therapeutics of Low-grade Gliomas. Journal of Neuro-Oncology. 53(3). 243–257. 28 indexed citations

13.

Geng, Ling, Edwin F. Donnelly, Gerald McMahon, et al.. (2001). Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.. PubMed. 61(6). 2413–9. 281 indexed citations

14.

Poss, Kenneth D., Jiaxiang Shen, Alex Nechiporuk, et al.. (2000). Roles for Fgf Signaling during Zebrafish Fin Regeneration. Developmental Biology. 222(2). 347–358. 268 indexed citations

15.

Bergers, Gabriele, Rolf A. Brekken, Gerald McMahon, et al.. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology. 2(10). 737–744. 2218 indexed citations breakdown →

16.

McMahon, Gerald, et al.. (1998). Fibroblast growth factor receptors regulate the ability for hindlimb regeneration in Xenopus laevis. Wound Repair and Regeneration. 6(4). 388–97. 28 indexed citations

17.

Gazit, Aviv, et al.. (1996). Tyrphostins IV—Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorganic & Medicinal Chemistry. 4(8). 1203–1207. 46 indexed citations

18.

Yu, Ker, William Bayona, Caleb B. Kallen, et al.. (1995). Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids. Journal of Biological Chemistry. 270(41). 23975–23983. 598 indexed citations breakdown →

19.

Soltis, D A, Gerald McMahon, H Chamberlin, et al.. (1995). Expression, Purification, and Characterization of the Human Squalene Synthase: Use of Yeast and Baculoviral Systems. Archives of Biochemistry and Biophysics. 316(2). 713–723. 19 indexed citations

20.

McMahon, Gerald. (1994). The genetics of human cancer: implications for ecotoxicology.. Environmental Health Perspectives. 102(suppl 12). 75–80. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact